Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
about
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalFirst-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.Proteasome inhibitors in the treatment of multiple myelomaRetrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaNew therapies in multiple myeloma.Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study.Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitorsProteasome inhibitors in multiple myeloma: 10 years later.Is there a role for 'modified VAD' in the treatment of multiple myeloma?Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
P2860
Q30276010-0A57A18D-5D52-493C-AA88-21A24543F2F0Q33386405-0578E6B0-36B3-41F0-B8C1-64237BBBD611Q33394873-461A328E-55D3-45E7-A63B-3629EF0FA320Q33416105-C3CBCE22-5EB2-46F7-AF64-98007C7E8823Q34011489-567D13F1-5CE5-4CA5-81FB-2E06C651475CQ34269238-29FA44FA-3809-452F-B5FC-589D5834812DQ34343763-4B68B5C9-7221-42D5-9632-5AA67A4368DFQ34480149-289355E6-D560-43E1-B047-BD5C1073DE54Q34611676-069A5150-1206-4EF4-A57A-9D852D4A5747Q34798095-C08327BC-ECB4-4FD3-A4CD-A098289B1A91Q35643032-6FF64BA5-7610-4444-A1F5-BED8CFE00463Q36384889-29BDB54E-5307-46EE-B0C2-2AD67E536416Q36986576-B39CC987-8E58-4A18-958D-C0E5949A8297Q37009725-981A9F38-A95E-47D3-80FA-A240E0528A14Q37187543-FD47DEAD-0989-40B6-91FA-CD8A575FAB73Q38014395-39F22A9C-1E5D-4A10-BDDD-6AD16F871D52Q39370010-C8FA1BDF-E930-4FDA-AD29-D7D9E5B7C182Q41867768-4DCE8B7A-4D0D-467F-B24E-F41DF5FD431DQ41874321-F362EE77-28B7-450E-8EF4-D80F90FE83AEQ42181436-B0371D8F-F30B-4AE0-AF29-222B3F245AEDQ43078127-63AD75ED-9A92-4B89-8EFF-56A61D612714Q47707509-2FF19854-63C7-45B8-94A1-937D19707676Q52686509-F3697B4B-CA64-4DFE-8576-0967332BAAD6Q54986945-EEFD6CE3-90F2-4713-9D05-1635D1FCE159Q55428315-3D683178-B96A-45C6-9E2E-8EC20EC5C972
P2860
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Bortezomib in combination with ...... response to bortezomib alone.
@ast
Bortezomib in combination with ...... response to bortezomib alone.
@en
type
label
Bortezomib in combination with ...... response to bortezomib alone.
@ast
Bortezomib in combination with ...... response to bortezomib alone.
@en
prefLabel
Bortezomib in combination with ...... response to bortezomib alone.
@ast
Bortezomib in combination with ...... response to bortezomib alone.
@en
P2093
P50
P1433
P1476
Bortezomib in combination with ...... l response to bortezomib alone
@en
P2093
Bart Barlogie
David Irwin
David P Schenkein
Dixie L Esseltine
Gordan Srkalovic
James R Berenson
SUMMIT/CREST Investigators
Seema Singhal
Sundar Jagannath
P304
P577
2006-07-01T00:00:00Z